A Phase I Study of EZN-3042, a Novel Survivin Messenger Ribonucleic Acid (mRNA) Antagonist, Administered in Combination with Chemotherapy in Children with Relapsed Acute Lymphoblastic Leukemia (ALL): A Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

To address therapeutic challenges in childhood relapsed ALL, a phase 1 study combining a survivin mRNA antagonist, EZN-3042, with re-induction chemotherapy was developed for pediatric patients with second or greater bone marrow relapses of B lymphoblastic leukemia. EZN-3042 was administered as a sin...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Pediatr Hematol Oncol
Autori principali: Raetz, Elizabeth A., Morrison, Debra, Romanos-Sirakis, Eleny, Gaynon, Paul, Sposto, Richard, Bhojwani, Deepa, Bostrom, Bruce C., Brown, Patrick, Eckroth, Elena, Cassar, Jeannette, Malvar, Jemily, Buchbinder, Aby, Carroll, William L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4238428/
https://ncbi.nlm.nih.gov/pubmed/24276047
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MPH.0b013e3182a8f58f
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi